Anavex life sciences to present at the h. c. wainwright global investment conference 2022

New york, may 19, 2022 (globe newswire) -- anavex life sciences corp. (“anavex” or the “company”) (nasdaq: avxl), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including alzheimer's disease, parkinson's disease, rett syndrome and other central nervous system (cns) diseases, today announced that christopher u missling, phd, president & chief executive officer of anavex will present at the h. c. wainwright global investment conference 2022 on wednesday, may 25, 2022, at 12:00 pm et.
AVXL Ratings Summary
AVXL Quant Ranking